Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702830 · ClinicalTrials.gov registry record
MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment
A clinical trial of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 33
- Enrollment target
- 1
- Study location
NCT02702830 is a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 33 participants, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02702830, a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot research trial studies magnetic resonance imaging (MRI) and cardio (heart)-pulmonary (lung) exercise testing in evaluating exercise intolerance in patients with stage I-III breast cancer after treatment with chemotherapy drugs called anthracyclines. Anthracyclines are related with heart problems, cardiac abnormalities, bone and muscle dysfunction. Patients with breast cancer who are exposed to anthracycline drugs may also experience progressive fatigue and exercise intolerance which may limit daily activities and is an important barrier for patients returning to work. Using MRI and cardio-pulmonary exercise testing (CPET) may help doctors understand the causes of fatigue and exercise intolerance in patients receiving anthracycline chemotherapy and this may also allow doctors to plan better treatments to protect patients' heart, cardiovascular system, bone and muscle function.
Conditions Studied
Interventions
- DEVICE Magnetic Resonance Imaging
- OTHER Cardiopulmonary Exercise Testing
Study Locations (1)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-08-25 |
| Est. Completion | 2017-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702830
The ClinicalTrials.gov registry entry for NCT02702830 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02702830 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02702830 about?
NCT02702830 is a clinical study titled "MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment". This pilot research trial studies magnetic resonance imaging (MRI) and cardio (heart)-pulmonary (lung) exercise testing in evaluating exercise intolerance in patients with stage I-III breast cancer after treatment with chemotherapy drugs called anthracyclines. Anthracyclines are related with heart p...
What is the current status of trial NCT02702830?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2016-08-25. Estimated completion is 2017-08.
What conditions does trial NCT02702830 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Healthy Subject.
What interventions are being tested in trial NCT02702830?
The interventions under investigation include: Magnetic Resonance Imaging (DEVICE), Cardiopulmonary Exercise Testing (OTHER).
Who is sponsoring clinical trial NCT02702830?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02702830 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Stage IIIA Breast Cancer
All registered trials for this condition
Stage IIIB Breast Cancer
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.